Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.

Familial cancer - 1 Oct 2017

Gorodetska I, Serga S, Lahuta T, Ostapchenko L, Demydov S, Khranovska N, Skachkova O, Inomistova M, Kolesnik O, Svintsitsky V, Tsip N, Peresunko A, Kmit' N, Manzhura O, Rossokha Z, Popova O, Salomakhina H, Kyriachenko S, Kozeretska I

Abstract excerpt

Ovarian cancer is the seventh most common cancer in women worldwide and the leading cause of gynecological malignant diseases-related deaths in women. The most significant risk factor for ovarian cancer is an inherited genetic mutation in one of two genes: breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2). The germline mutation c.5266dupC (also known as 5382insC or 5385insC) is the most common mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Mutation, Missense

Share to Mutation Rate

Share to Ovarian Neoplasms

Share to Prevalence

Share to Ukraine

Source

Identifiers

PMID: 28285342
DOI: 10.1007/s10689-017-9978-9

Genes

BRCA1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.PMID 28285342Read ↗

Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.Semantic proximity Read ↗

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?Semantic proximity Read ↗

New Germinal Mutation of BRCA1 gene (c.829_832delAATA) in a Polish Patient with Breast/Ovarian CancerSemantic proximity Read ↗

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East PolandSemantic proximity Read ↗

A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.Semantic proximity Read ↗

High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: updateSemantic proximity Read ↗

Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.Semantic proximity Read ↗

The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.Semantic proximity Read ↗

Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.Semantic proximity Read ↗

Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.Semantic proximity Read ↗

Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.